Search Results

You are looking at 21 - 27 of 27 items for :

  • "suboptimal response" x
Clear All
Full access

Paul D. Harker-Murray, Lauren Pommert and Matthew J. Barth

.07.001 46. Harker-Murray P , Leblanc T , Mascarin M , . Response-adapted therapy with nivolumab and brentuximab vedotin (BV), followed by BV and bendamustine for suboptimal response, in children, adolescents, and young adults with standard

Full access

achievement, and by minimizing suboptimal responses requiring the need to switch therapies. There is a need to try alternate therapies for nonresponders, but the potential for slower response achievement in second-line treatment needs to be recognized. AB

Full access

Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, Lynn Wilson, Joachim Yahalom, Nadeem Zafar, Mary Dwyer and Hema Sundar

characteristics and does not indicate a suboptimal response to therapy . Blood 2014 ; 123 : 1810 – 1817 . 78. Kovacs G Boettcher S Bahlo J . Value of minimal residual disease (MRD) negative status at response evaluation in chronic lymphocytic

Full access

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, Asher A. Chanan-Khan, Julio C. Chavez, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Megan S. Lim, Shuo Ma, Sami Malek, Anthony Mato, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Suchitra Sundaram, Nina Wagner, Mary Dwyer and Hema Sundar

lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy . Blood 2014 ; 123 : 1810 – 1817 . 10.1182/blood-2013-09-527853 24415539 72. Brown JR , Byrd JC , Coutre

Full access

Arti Hurria, Tanya Wildes, Sarah L. Blair, Ilene S. Browner, Harvey Jay Cohen, Mollie deShazo, Efrat Dotan, Barish H. Edil, Martine Extermann, Apar Kishor P. Ganti, Holly M. Holmes, Reshma Jagsi, Mohana B. Karlekar, Nancy L. Keating, Beatriz Korc-Grodzicki, June M. McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O’Connor, Hope S. Rugo, Randall W. Rupper, Rebecca A. Silliman, Derek L. Stirewalt, William P. Tew, Louise C. Walter, Alva B. Weir III, Mary Anne Bergman and Hema Sundar

patients with CML; nonadherence rates were significantly higher for patients with suboptimal response compared with those with optimal response to imatinib (23% and 7%, respectively). 226 Marin et al 227 also identified adherence as the only independent

Full access

George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W.T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott Schuetze, Hema M. Sundar, Jonathan C. Trent and Jeffrey D. Wayne

Treatment interruptions and nonadherence might lead to undesirable clinical outcomes. The results of the Adherence Assessment with Glivec: Indicators and Outcomes (ADAGIO) study showed that patients with suboptimal response had significantly higher mean

Full access

-hospital mortality was 0.33 K/mm 3 (sensitivity, 63.3%; specificity, 64.6%). Conclusions: Higher day 5 WBC count correlated with in-hospital mortality. This is in accordance with the current understanding that suboptimal response to chemotherapy is associated with